![Serum free light chain assays not total light chain assays are the standard of care to assess Monoclonal Gammopathies | Hematology, Transfusion and Cell Therapy Serum free light chain assays not total light chain assays are the standard of care to assess Monoclonal Gammopathies | Hematology, Transfusion and Cell Therapy](https://multimedia.elsevier.es/PublicationsMultimediaV1/item/multimedia/S151684841500170X:gr1.jpeg?xkr=ue/ImdikoIMrsJoerZ+w92xcqUtYYCc6yiYRjTD2AR1aFJOKb7qLd+WBf18Ptk/O8dVG5SMqADZji5skBxdmL4Eg+W9M/1HLX6WWOJItH9fTBgdwdPEZR3glHibTrvPAkYyjMi4Vjd55uqJ5DGqlkRjnxsYiTDCVHBAPb+c3uF5KJgKx9Yu19zRC8/kXWnMHN6Ds6zmD73kq5Ioodt3NBUa3ChmlLkrLmWBRMQjlKUpU5vh8NPt70tzEUPueps4+UMKJIGHvgVC7vk0IbGgjd78Ub7YIgCdbhdCEpxhTRgh0xNGSd+WSX2g7oP8mFZzQ)
Serum free light chain assays not total light chain assays are the standard of care to assess Monoclonal Gammopathies | Hematology, Transfusion and Cell Therapy
![Comparison of three different serum-free light-chain assays—implications on diagnostic and therapeutic monitoring of multiple myeloma | Blood Cancer Journal Comparison of three different serum-free light-chain assays—implications on diagnostic and therapeutic monitoring of multiple myeloma | Blood Cancer Journal](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41408-019-0267-8/MediaObjects/41408_2019_267_Fig1_HTML.png)
Comparison of three different serum-free light-chain assays—implications on diagnostic and therapeutic monitoring of multiple myeloma | Blood Cancer Journal
Excluding myeloma diagnosis using revised thresholds for serum free light chain ratios and M-protein levels | Haematologica
![A new free light chain immunoassay shows advantages in the classification and in the follow-up of patients with paraproteinemia compared to a nephelometric assay A new free light chain immunoassay shows advantages in the classification and in the follow-up of patients with paraproteinemia compared to a nephelometric assay](https://www.oatext.com/img/HMO-4-195-g003.gif)
A new free light chain immunoassay shows advantages in the classification and in the follow-up of patients with paraproteinemia compared to a nephelometric assay
![Measurement of kappa () and lambda () light chains in free and total... | Download High-Quality Scientific Diagram Measurement of kappa () and lambda () light chains in free and total... | Download High-Quality Scientific Diagram](https://www.researchgate.net/publication/292707470/figure/fig4/AS:669620646187022@1536661411380/Measurement-of-kappa-and-lambda-light-chains-in-free-and-total-assays-Total-light.png)
Measurement of kappa () and lambda () light chains in free and total... | Download High-Quality Scientific Diagram
![The role of free kappa and lambda light chains in the pathogenesis and treatment of inflammatory diseases - ScienceDirect The role of free kappa and lambda light chains in the pathogenesis and treatment of inflammatory diseases - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0753332216323745-gr2.jpg)
The role of free kappa and lambda light chains in the pathogenesis and treatment of inflammatory diseases - ScienceDirect
![PDF] Serum free light chain ratio, total kappa/lambda ratio, and immunofixation results are not prognostic factors after stem cell transplantation for newly diagnosed multiple myeloma. | Semantic Scholar PDF] Serum free light chain ratio, total kappa/lambda ratio, and immunofixation results are not prognostic factors after stem cell transplantation for newly diagnosed multiple myeloma. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/92e61d19dc92e499c7b7b01818ac923837d9f518/2-Table2-1.png)
PDF] Serum free light chain ratio, total kappa/lambda ratio, and immunofixation results are not prognostic factors after stem cell transplantation for newly diagnosed multiple myeloma. | Semantic Scholar
![Exploiting endogenous and therapy-induced apoptotic vulnerabilities in immunoglobulin light chain amyloidosis with BH3 mimetics | Nature Communications Exploiting endogenous and therapy-induced apoptotic vulnerabilities in immunoglobulin light chain amyloidosis with BH3 mimetics | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-022-33461-z/MediaObjects/41467_2022_33461_Fig1_HTML.png)